Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.

Name: Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Author: Lin, Z Ping

Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. — المؤلف: Lin, Z Ping — PloS one 20190415

المؤلف: Lin, Z Ping
النشر: PloS one 20190415
الوصف: e0207399 p.
الموضوعات: Animals؛ Antineoplastic Combined Chemotherapy Protocols؛ BRCA1 Protein؛ Breast Neoplasms؛ Cell Line, Tumor؛ Drug Resistance, Neoplasm؛ Female؛ Humans